Axsome Therapeutics Inc
AXSM
Market Cap$5.18B
Close$
$20.54
81% downside
Current Fair Value
81% downsideOvervalued by 81% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.18 Billion |
|---|---|
| Enterprise Value | $5.09 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.99 |
| Beta | 0.45 |
| Outstanding Shares | 48,871,163 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -18.47 |
|---|---|
| PEG | 141.15 |
| Price to Sales | 13.52 |
| Price to Book Ratio | 108.14 |
| Enterprise Value to Revenue | 11.77 |
| Enterprise Value to EBIT | -18.63 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 3.94 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...